Key facts
- It has raised $59.2M; the latest was Later Stage VC ($42.0M) in May 2024.
- Notable investors include Y Combinator, Creative Destruction Lab, Lux Capital, Raptor Group, 2048 Ventures — 22 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Nomic
- ·The full record, as it builds
Funding rounds
No funding rounds for Nomic are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nomic
Developer of a throughput proteomic platform designed to make the human proteome easily accessible, like the human genome. The company's reagent platform and research provide features such as cost-effective measurement of protein data with the sample, which fits within industry cytometers for high-throughput analysis and development of custom protein panels, enabling nanotechnology developers and businesses to use deoxyribonucleic acid as a flexible, programmable linker to completely overcome cross-reactivity.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2017
- Employees
- 93
- Website
- nomic.bio/
- Ownership
- Privately Held (backing)
Nomic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nomic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nomic in its N-PORT filings yet. We sweep new filings monthly.